Table 4 Base Case Values of Cost-Effectiveness Analysis of Three Strategies in China and the USA
Parameters | China | USA | ||||
|---|---|---|---|---|---|---|
TACE | Full-dose Sorafenib | Dose-adjusted Sorafenib | TACE | Full-dose Sorafenib | Dose-adjusted Sorafenib | |
LYG (months) | 6.357 | 7.236 | 7.898 | 6.357 | 7.236 | 7.898 |
QALYs (years) | 0.375 | 0.435 | 0.482 | 0.375 | 0.435 | 0.482 |
Lifetime cost ($) | 10,642.22 | 16,703.95 | 10,488.72 | 95,061.13 | 34,190.70 | 23,377.97.54 |